Literature DB >> 26892836

Association between health status and long-term mortality after percutaneous revascularization of peripheral artery disease.

Matthew C Bunte1,2, John A House1, John A Spertus1,2, David J Cohen1,2, Steven P Marso3, David M Safley1,2.   

Abstract

OBJECTIVES: To explore the association of health status change and long-term survival among patients with symptomatic peripheral artery disease (PAD).
BACKGROUND: Early gains in health status after successful endovascular therapy (EVT) for symptomatic PAD can be maintained up to 1 year. Whether such health status improvements are associated with long-term survival benefits is unknown.
METHODS: Between February 2001 and August 2004, 258 patients with symptomatic PAD treated with EVT participated in a prospective study evaluating baseline and 1 year health status using the Peripheral Artery Questionnaire (range 0-100, higher scores = better). All-cause mortality was assessed for all patients at a median of 9.4 years following EVT.
RESULTS: The mean age at enrollment was 68 ± 11 years; 61% were male, 97% were Caucasian, and 38% had diabetes. Patients with a clinically meaningful health status improvement (≥8 points) 1 year after their index procedure (79%) were identified as responders. Responders had a significantly better 10 year survival compared with nonresponders (60% vs 38%, p = 0.025). Responder status was associated with a survival advantage that persisted in risk-adjusted analysis (adjusted hazard ratio for long-term mortality, 0.66 [95% CI, 0.45-0.97]; p = 0.036).
CONCLUSIONS: Among patients with symptomatic PAD undergoing EVT, improvement of PAD-specific health status at 1 year follow-up was associated with improved long-term survival. Whether additional treatment for patients with poor response to EVT could improve long-term survival warrants further investigation.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  angioplasty; peripheral artery disease; quality of life

Mesh:

Year:  2016        PMID: 26892836     DOI: 10.1002/ccd.26442

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  5 in total

1.  Major Limb Outcomes Following Lower Extremity Endovascular Revascularization in Patients With and Without Diabetes Mellitus.

Authors:  Andrew N Shammas; Haekyung Jeon-Slaughter; Shirling Tsai; Houman Khalili; Mujtaba Ali; Hao Xu; Gerardo Rodriguez; Ian Cawich; Ehrin J Armstrong; Emmanouil S Brilakis; Subhash Banerjee
Journal:  J Endovasc Ther       Date:  2017-04-25       Impact factor: 3.487

2.  Sex-Related Differences in the Outcomes of Endovascular Interventions for Chronic Limb-Threatening Ischemia: Results from the LIBERTY 360 Study.

Authors:  Stefanos Giannopoulos; Nicolas W Shammas; Ian Cawich; Cezar S Staniloae; George L Adams; Ehrin J Armstrong
Journal:  Vasc Health Risk Manag       Date:  2020-07-08

3.  The prognostic role of RBP-4 and adiponectin in patients with peripheral arterial disease undergoing lower limb endovascular revascularization.

Authors:  Nikolaos P E Kadoglou; Emmanouil Korakas; Christos Karkos; Eirini Maratou; Ioannis Kanonidis; Panagiotis Plotas; Nikolaos Papanas; Paraskevi Moutsatsou; Ignatios Ikonomidis; Vaia Lambadiari
Journal:  Cardiovasc Diabetol       Date:  2021-11-10       Impact factor: 9.951

Review 4.  Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis.

Authors:  Rupert Bauersachs; Olivia Wu; Neil Hawkins; Kevin Bowrin; Piotr Wojciechowski; Emilie Clay; Maria Huelsebeck
Journal:  Cardiovasc Ther       Date:  2021-08-24       Impact factor: 3.023

5.  Association of Disease-Specific Health Status With Long-Term Survival in Peripheral Artery Disease.

Authors:  Andy T Tran; John A Spertus; Carlos I Mena-Hurtado; Philip G Jones; Herbert D Aronow; David M Safley; Ali O Malik; Poghni A Peri-Okonny; Mehdi H Shishehbor; Clementine Labrosciano; Kim G Smolderen
Journal:  J Am Heart Assoc       Date:  2022-02-08       Impact factor: 6.106

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.